Your treatment will begin after you have completed at least 2 consolidation treatments following your initial intensive chemotherapy. This must occur within 17 weeks after achieving complete remission.

You will receive two medications in tablet form: azacitidine (brand name Onureg) and ivosidenib (brand name Tibsovo). Both medications are taken by mouth.

The azacitidine tablets are available in two strengths: 200 mg and 300 mg. The ivosidenib tablets are 250 mg. Your doctor will determine the specific doses you will take.

You will need to take both medications as prescribed by your doctor throughout the study period.

The medications are film-coated tablets that should be swallowed whole.

It is important to follow the dosing schedule provided by your doctor and take the medications at the same time each day.

You will attend regular appointments to monitor your health and how you are responding to the treatment.

During these visits, blood tests will be performed to check your blood cell counts and organ function.

Your doctor will check that your bone marrow function remains adequate, with specific attention to your white blood cell count and platelet count.

Tests will also monitor your kidney function (measured by estimated glomerular filtration rate) and liver function (measured by specific enzymes called AST and ALT, as well as bilirubin levels).

Your doctor will perform tests to check if your leukemia remains in remission.

Some of these tests may include checking for minimal residual disease (MRD), which means looking for very small amounts of leukemia cells that standard tests might not detect.

These tests may be done using flow cytometry (a laboratory technique that examines cells) or molecular tests if you have a specific genetic marker called NPM1.

Throughout the study, your doctor will monitor you for any side effects or adverse events related to the medications.

Any health changes or symptoms you experience will be recorded and evaluated according to a standardized classification system.

You should report any new symptoms or health concerns to your doctor promptly.

If you are a woman of childbearing potential, you must use effective contraception starting from the beginning of the study and continuing for 180 days (approximately 6 months) after your last dose of study medication.

If you are a woman of childbearing potential, you will need to have pregnancy tests performed at scheduled times during the study.

If you are a woman, you must not breastfeed during the study and for one month after your last dose of study medication.

If you are a woman, you must not donate eggs during the study and for 180 days after your last dose of study medication.

If you are a man with a partner of childbearing potential, you must use contraception during the study and for 90 days (approximately 3 months) after your last dose of study medication.

If you are a man, you must not donate sperm during the study and for 90 days after your last dose of study medication.

Your health will be monitored at specific time points, including assessments at 12 months and 24 months after starting treatment.

These assessments will evaluate whether your leukemia remains in remission and your overall health status.

Your doctor will continue to track your progress even after you complete the active treatment phase.